Design and Rationale of the Best Endovascular Versus Best Surgical Therapy for Patients With Critical Limb Ischemia (BEST-CLI) Trial

Matthew T. Menard, Alik Farber, Susan F. Assmann, Niteesh K. Choudhry, Michael S. Conte, Mark A. Creager, Michael D. Dake, Michael R. Jaff, John A. Kaufman, Richard J. Powell, Diane M. Reid, Flora Sandra Siami, George Sopko, Christopher J. White, Kenneth Rosenfield

Research output: Contribution to journalArticle

65 Citations (Scopus)

Abstract

BACKGROUND: Critical limb ischemia (CLI) is increasing in prevalence, and remains a significant source of mortality and limb loss. The decision to recommend surgical or endovascular revascularization for patients who are candidates for both varies significantly among providers and is driven more by individual preference than scientific evidence.

METHODS AND RESULTS: The Best Endovascular Versus Best Surgical Therapy for Patients With Critical Limb Ischemia (BEST-CLI) Trial is a prospective, randomized, multidisciplinary, controlled, superiority trial designed to compare treatment efficacy, functional outcomes, quality of life, and cost in patients undergoing best endovascular or best open surgical revascularization. Approximately 140 clinical sites in the United States and Canada will enroll 2100 patients with CLI who are candidates for both treatment options. A pragmatic trial design requires consensus on patient eligibility by at least 2 investigators, but leaves the choice of specific procedural strategy within the assigned revascularization approach to the individual treating investigator. Patients with suitable single-segment of saphenous vein available for potential bypass will be randomized within Cohort 1 (n=1620), while patients without will be randomized within Cohort 2 (n=480). The primary efficacy end point of the trial is Major Adverse Limb Event-Free Survival. Key secondary end points include Re-intervention and Amputation-Free-Survival and Amputation Free-Survival.

CONCLUSIONS: The BEST-CLI trial is the first randomized controlled trial comparing endovascular therapy to open surgical bypass in patients with CLI to be carried out in North America. This landmark comparative effectiveness trial aims to provide Level I data to clarify the appropriate role for both treatment strategies and help define an evidence-based standard of care for this challenging patient population.

CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov/. Unique identifier: NCT02060630.

Original languageEnglish (US)
JournalJournal of the American Heart Association
Volume5
Issue number7
DOIs
StatePublished - Jul 8 2016
Externally publishedYes

Fingerprint

Ischemia
Extremities
Therapeutics
Amputation
Pragmatic Clinical Trials
Research Personnel
Survival
Saphenous Vein
Standard of Care
North America
Disease-Free Survival
Canada
Randomized Controlled Trials
Quality of Life
Clinical Trials
Costs and Cost Analysis
Mortality
Population

Keywords

  • atherosclerosis
  • cost‐effectiveness
  • critical limb ischemia
  • endovascular
  • outcome
  • quality
  • stent treatment
  • surgery

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Design and Rationale of the Best Endovascular Versus Best Surgical Therapy for Patients With Critical Limb Ischemia (BEST-CLI) Trial. / Menard, Matthew T.; Farber, Alik; Assmann, Susan F.; Choudhry, Niteesh K.; Conte, Michael S.; Creager, Mark A.; Dake, Michael D.; Jaff, Michael R.; Kaufman, John A.; Powell, Richard J.; Reid, Diane M.; Siami, Flora Sandra; Sopko, George; White, Christopher J.; Rosenfield, Kenneth.

In: Journal of the American Heart Association, Vol. 5, No. 7, 08.07.2016.

Research output: Contribution to journalArticle

Menard, MT, Farber, A, Assmann, SF, Choudhry, NK, Conte, MS, Creager, MA, Dake, MD, Jaff, MR, Kaufman, JA, Powell, RJ, Reid, DM, Siami, FS, Sopko, G, White, CJ & Rosenfield, K 2016, 'Design and Rationale of the Best Endovascular Versus Best Surgical Therapy for Patients With Critical Limb Ischemia (BEST-CLI) Trial', Journal of the American Heart Association, vol. 5, no. 7. https://doi.org/10.1161/JAHA.116.003219
Menard, Matthew T. ; Farber, Alik ; Assmann, Susan F. ; Choudhry, Niteesh K. ; Conte, Michael S. ; Creager, Mark A. ; Dake, Michael D. ; Jaff, Michael R. ; Kaufman, John A. ; Powell, Richard J. ; Reid, Diane M. ; Siami, Flora Sandra ; Sopko, George ; White, Christopher J. ; Rosenfield, Kenneth. / Design and Rationale of the Best Endovascular Versus Best Surgical Therapy for Patients With Critical Limb Ischemia (BEST-CLI) Trial. In: Journal of the American Heart Association. 2016 ; Vol. 5, No. 7.
@article{9f3917a256f84827aea41bd33b64f72a,
title = "Design and Rationale of the Best Endovascular Versus Best Surgical Therapy for Patients With Critical Limb Ischemia (BEST-CLI) Trial",
abstract = "BACKGROUND: Critical limb ischemia (CLI) is increasing in prevalence, and remains a significant source of mortality and limb loss. The decision to recommend surgical or endovascular revascularization for patients who are candidates for both varies significantly among providers and is driven more by individual preference than scientific evidence.METHODS AND RESULTS: The Best Endovascular Versus Best Surgical Therapy for Patients With Critical Limb Ischemia (BEST-CLI) Trial is a prospective, randomized, multidisciplinary, controlled, superiority trial designed to compare treatment efficacy, functional outcomes, quality of life, and cost in patients undergoing best endovascular or best open surgical revascularization. Approximately 140 clinical sites in the United States and Canada will enroll 2100 patients with CLI who are candidates for both treatment options. A pragmatic trial design requires consensus on patient eligibility by at least 2 investigators, but leaves the choice of specific procedural strategy within the assigned revascularization approach to the individual treating investigator. Patients with suitable single-segment of saphenous vein available for potential bypass will be randomized within Cohort 1 (n=1620), while patients without will be randomized within Cohort 2 (n=480). The primary efficacy end point of the trial is Major Adverse Limb Event-Free Survival. Key secondary end points include Re-intervention and Amputation-Free-Survival and Amputation Free-Survival.CONCLUSIONS: The BEST-CLI trial is the first randomized controlled trial comparing endovascular therapy to open surgical bypass in patients with CLI to be carried out in North America. This landmark comparative effectiveness trial aims to provide Level I data to clarify the appropriate role for both treatment strategies and help define an evidence-based standard of care for this challenging patient population.CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov/. Unique identifier: NCT02060630.",
keywords = "atherosclerosis, cost‐effectiveness, critical limb ischemia, endovascular, outcome, quality, stent treatment, surgery",
author = "Menard, {Matthew T.} and Alik Farber and Assmann, {Susan F.} and Choudhry, {Niteesh K.} and Conte, {Michael S.} and Creager, {Mark A.} and Dake, {Michael D.} and Jaff, {Michael R.} and Kaufman, {John A.} and Powell, {Richard J.} and Reid, {Diane M.} and Siami, {Flora Sandra} and George Sopko and White, {Christopher J.} and Kenneth Rosenfield",
year = "2016",
month = "7",
day = "8",
doi = "10.1161/JAHA.116.003219",
language = "English (US)",
volume = "5",
journal = "Journal of the American Heart Association",
issn = "2047-9980",
publisher = "Wiley-Blackwell",
number = "7",

}

TY - JOUR

T1 - Design and Rationale of the Best Endovascular Versus Best Surgical Therapy for Patients With Critical Limb Ischemia (BEST-CLI) Trial

AU - Menard, Matthew T.

AU - Farber, Alik

AU - Assmann, Susan F.

AU - Choudhry, Niteesh K.

AU - Conte, Michael S.

AU - Creager, Mark A.

AU - Dake, Michael D.

AU - Jaff, Michael R.

AU - Kaufman, John A.

AU - Powell, Richard J.

AU - Reid, Diane M.

AU - Siami, Flora Sandra

AU - Sopko, George

AU - White, Christopher J.

AU - Rosenfield, Kenneth

PY - 2016/7/8

Y1 - 2016/7/8

N2 - BACKGROUND: Critical limb ischemia (CLI) is increasing in prevalence, and remains a significant source of mortality and limb loss. The decision to recommend surgical or endovascular revascularization for patients who are candidates for both varies significantly among providers and is driven more by individual preference than scientific evidence.METHODS AND RESULTS: The Best Endovascular Versus Best Surgical Therapy for Patients With Critical Limb Ischemia (BEST-CLI) Trial is a prospective, randomized, multidisciplinary, controlled, superiority trial designed to compare treatment efficacy, functional outcomes, quality of life, and cost in patients undergoing best endovascular or best open surgical revascularization. Approximately 140 clinical sites in the United States and Canada will enroll 2100 patients with CLI who are candidates for both treatment options. A pragmatic trial design requires consensus on patient eligibility by at least 2 investigators, but leaves the choice of specific procedural strategy within the assigned revascularization approach to the individual treating investigator. Patients with suitable single-segment of saphenous vein available for potential bypass will be randomized within Cohort 1 (n=1620), while patients without will be randomized within Cohort 2 (n=480). The primary efficacy end point of the trial is Major Adverse Limb Event-Free Survival. Key secondary end points include Re-intervention and Amputation-Free-Survival and Amputation Free-Survival.CONCLUSIONS: The BEST-CLI trial is the first randomized controlled trial comparing endovascular therapy to open surgical bypass in patients with CLI to be carried out in North America. This landmark comparative effectiveness trial aims to provide Level I data to clarify the appropriate role for both treatment strategies and help define an evidence-based standard of care for this challenging patient population.CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov/. Unique identifier: NCT02060630.

AB - BACKGROUND: Critical limb ischemia (CLI) is increasing in prevalence, and remains a significant source of mortality and limb loss. The decision to recommend surgical or endovascular revascularization for patients who are candidates for both varies significantly among providers and is driven more by individual preference than scientific evidence.METHODS AND RESULTS: The Best Endovascular Versus Best Surgical Therapy for Patients With Critical Limb Ischemia (BEST-CLI) Trial is a prospective, randomized, multidisciplinary, controlled, superiority trial designed to compare treatment efficacy, functional outcomes, quality of life, and cost in patients undergoing best endovascular or best open surgical revascularization. Approximately 140 clinical sites in the United States and Canada will enroll 2100 patients with CLI who are candidates for both treatment options. A pragmatic trial design requires consensus on patient eligibility by at least 2 investigators, but leaves the choice of specific procedural strategy within the assigned revascularization approach to the individual treating investigator. Patients with suitable single-segment of saphenous vein available for potential bypass will be randomized within Cohort 1 (n=1620), while patients without will be randomized within Cohort 2 (n=480). The primary efficacy end point of the trial is Major Adverse Limb Event-Free Survival. Key secondary end points include Re-intervention and Amputation-Free-Survival and Amputation Free-Survival.CONCLUSIONS: The BEST-CLI trial is the first randomized controlled trial comparing endovascular therapy to open surgical bypass in patients with CLI to be carried out in North America. This landmark comparative effectiveness trial aims to provide Level I data to clarify the appropriate role for both treatment strategies and help define an evidence-based standard of care for this challenging patient population.CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov/. Unique identifier: NCT02060630.

KW - atherosclerosis

KW - cost‐effectiveness

KW - critical limb ischemia

KW - endovascular

KW - outcome

KW - quality

KW - stent treatment

KW - surgery

UR - http://www.scopus.com/inward/record.url?scp=85019218379&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019218379&partnerID=8YFLogxK

U2 - 10.1161/JAHA.116.003219

DO - 10.1161/JAHA.116.003219

M3 - Article

C2 - 27402237

AN - SCOPUS:85019218379

VL - 5

JO - Journal of the American Heart Association

JF - Journal of the American Heart Association

SN - 2047-9980

IS - 7

ER -